BioLineRx (BLRX) Other financing activities (2013 - 2025)

BioLineRx's Other financing activities history runs 13 years deep, the most recent figure standing at $725000.0 for Q3 2025.

• On a quarterly basis, Other financing activities rose 192.12% year-over-year to $725000.0 in Q3 2025; TTM through Sep 2025 was -$900000.0, a 109.75% decrease from a year earlier, with the FY2024 full-year figure at $22000.0, down 99.25% from the prior year.
• Other financing activities advanced to $725000.0 in Q3 2025 per BLRX's latest filing, from -$1.8 million in the prior quarter.
• Across five years, Other financing activities topped out at $16.0 million in Q1 2021 and bottomed at -$13.1 million in Q4 2022.
• The 5-year median for Other financing activities is $725000.0 (2025), against an average of $1.3 million.
• Biggest YoY gain for Other financing activities was 250.0% in 2024; the steepest drop was 2314.57% in 2024.
• Year by year, Other financing activities stood at -$5.1 million in 2021, then slumped by 154.86% to -$13.1 million in 2022, then jumped by 103.04% to $398000.0 in 2023, then plunged by 2314.57% to -$8.8 million in 2024, then soared by 108.23% to $725000.0 in 2025.
• Per Business Quant, the three latest BLRX Other financing activities figures stand at $725000.0 (Q3 2025), -$1.8 million (Q2 2025), and $9.0 million (Q1 2025).